(32) revealed that in B-ALL, patients with RAS pathway mutations (NRAS, KRAS, and FLT3) are more chemoresistant, and NRAS or KRAS mutations are common genetic abnormalities in relapsed ALL and are associated with poor prognosis. The gene discussed is KRAS; the disease is acute lymphoblastic leukemia.